12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tresiba insulin degludec regulatory update

EMA's CHMP recommended approval of an MAA from Novo Nordisk for Tresiba insulin degludec to treat Type I and II diabetes. The long-acting insulin analog is under...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >